Re: Randomized controlled trial of zoledronic acid to prevent bone loss in men receiving androgen deprivation therapy for nonmetastatic prostate cancer.

Authors :: Pitts WR Jr
Source :: The Journal of urology [J Urol] 2003 Dec; Vol. 170 (6 Pt 1), pp. 2392-3; author reply 2393-4.
Publication Year :: 2003

Subjects :: Bone Resorption etiology
Gonadotropin-Releasing Hormone agonists
Gonadotropin-Releasing Hormone therapeutic use
Humans
Male
Zoledronic Acid
Androgen Antagonists therapeutic use
Antineoplastic Agents, Hormonal therapeutic use
Bone Resorption prevention & control
Diphosphonates therapeutic use
Imidazoles therapeutic use
Prostatic Neoplasms drug therapy

Full Text Access

Tools